Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Amdizalisib (HMPL-689) Discovered for the Treatment of Relapsed or Refractory Follicular Lymphoma

Hutchmed Limited discovered novel therapy amdizalisib (HMPL-689), for the treatment of relapsed or refractory follicular lymphoma (“FL”).

Amdizalisib is an inhibitor for PI3Kδ (phosphoinositide 3-kinase delta),a lipid kinase which helps in controlling the activation of several important signaling proteins. Moreover, when antigen is binded to B-cell receptors, PI3Kδ activates through the Lyn and Syk signaling cascade.

Novel Amdizalisib (HMPL-689), is an oral inhibitor targetingthe isoform PI3Kδ. Some of its properties include good oral absorption,signifying low risk of drug accumulation and drug-to-drug interaction, moderate tissue distribution and low clearance in preclinical PK studies.

The abnormal action of B-cell receptor signaling leads to the growth of B-cell type hematological cancers, resulting in 85% of all NHL cases. Hence, PI3Kδ is the promising drug considered for the treatment of hematologic cancers.

In US and Europe regions, Amdizalisib is being evaluated in an ongoing Phase I/Ib studyin patients with relapsed or refractory NHL.

Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) grants Breakthrough Therapy Designation (“BTD”) foramdizalisib (HMPL-689)to treat relapsed or refractory follicular lymphoma.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024